Evolution of the emergency drug innovation network and policy implications: Evidence from COVID-19 drug patents

Developing emergency drugs in time is key to responding to public health emergencies such as the coronavirus disease 2019 (COVID-19) pandemic. This research constructs patent assignee citation networks based on COVID-19 drug patents and applies technology life cycle analysis and social network analysis to examine these networks. The results reveal the evolution and structure of the emergency drug innovation network and identify innovation entities with different research and development (R&D) capabilities or a foundation for cooperation. This study attempts to provide the basis for theories and policies to accelerate R&D of emergency drugs. The key results are as follows: (1) Technologies of the emergency drug innovation network show fluctuating growth aligned closely with public health emergencies. (2) The network presents a sparse structure with many active factions, whose members have the advantage of cooperating. (3) Three types of innovation entities are identified: the main technology suppliers, potential suppliers of other supporting technologies, and peripheral suppliers of other supporting technologies.

[Male fertility in the context of COVID-19: Concern and considerations]

Since the outbreak of coronavirus disease 2019 (COVID-19), more than 130,000 people worldwide have been infected. Many studies show that the testis is one of the organs with a high expression of angiotensin-converting enzyme 2 (ACE2), the receptor/binding protein of SARS-CoV-2, which has aroused public concerns about the possible damage to male fertility. This article presents a review and analysis of the existing literature, aiming to achieve an objective understanding of the significance of the ACE2 expression in the testis. Hitherto, clinical and laboratory data available on COVID-19 are not sufficient to provide any direct evidence that the testis is a target organ of the virus. Whether the coronavirus damages fertility in male patients with COVID-19 requires further investigation. In the absence of sufficient research-based evidence, damage of the virus to male fertility should not be over-interpreted.